Navigation Links
Melanoma vaccine strategy shows promise in laboratory experiments

A novel approach to creating a vaccine to treat melanoma has demonstrated promising effectiveness in a new laboratory study led by researchers at The Wistar Institute. About a third of melanoma patients might benefit from such a vaccine. The study appears in the current issue of Cancer Research.

In the study, the scientists used a small protein called a peptide found in approximately 70 percent of melanomas, but not in normal cells, to stimulate immune cells called killer T cells to attack the melanoma cells. Another type of immune cell called a monocyte was used to present the peptide, BRAFV600E, to the killer T cells to trigger their attack on the melanoma cells.

"In our experiments, we saw a strong cancer-killing immune response when killer T cells are stimulated with this peptide," says Dorothee Herlyn, D.V.M., senior author on the study and a professor in the Immunology Program and Molecular and Cellular Oncogenesis Program at Wistar. "The results emphasize the potential of this approach for creating an effective melanoma vaccine, and we hope to move toward human clinical trials as soon as possible."

A substantial proportion of melanoma patients, about 50 percent, have killer T cells able to recognize the BRAFV600E peptide. Combining the prevalence of the peptide among melanoma patients ?about 70 percent ?with the number of patients whose immune cells are able to respond to the peptide suggests that a vaccine based on BRAFV600E could treat approximately a third of all melanoma patients.

Herlyn adds that the specificity of the peptide ?the fact that it is found only in melanoma cells, not normal cells ?suggests that the toxicity of any vaccine based on the peptide would be minimal. Killer T cells sparked into action by the vaccine would target only the cancer cells, sparing healthy cells entirely.

Looking ahead to possible human clinical trials, another member of the scientific team, University of Pennsylvania assistant pro
'"/>

Source:The Wistar Institute


Page: 1 2

Related biology news :

1. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
2. Research advances quest for HIV-1 vaccine
3. A much-needed shot in the arm for HIV vaccine development
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. Gene vaccine for Alzheimers disease shows promising results
6. Influenza vaccine uses insect cells to speed development
7. Norovirus, AIDS vaccine and Hepatitis Virus
8. HIV vaccine trial breaks ground for future research
9. Live vaccines more effective against horse herpes virus
10. NIAID begins clinical trial of West Nile virus vaccine
11. Designing vaccines by computer
Post Your Comments:
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... --  News Highlights: , ... Partners Data Lake, an agile data and analytics ... allow researcher and clinicians to explore and develop ... of patients , The Partners Data Lake ... Partners system, breaking down physical barriers for collaboration ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... , Results from the first ever European-wide retrospective analysis ... both D-penicillamine and trientine continue to be effective treatments, ... free from a liver transplant. , Wilson disease is ... not excreted by the body effectively, leading to excess ...
... Researchers at The Johns Hopkins University School of ... to become contaminated with unacceptably high levels of bacteria, ... operated faucets. The study will be presented on ... Healthcare Epidemiology of America (SHEA). Electronic-eye, non-touch faucets ...
... Va.--The Department of the Navy announced today the award ... academic institutions as part of the Office of Naval ... Young Investigator Program is an important part of the ... (STEM) outreach programs," said Secretary of the Navy Ray ...
Cached Biology News:European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease 2Electronic faucets unsafe for use in high-risk patient hospital settings 2
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short ... Side” published as a tribute to his mentor ... Short Story” category of the 2014 USA Best ... of USA Book News, said this year’s contest yielded ... Simon & Schuster, Penguin, John Wiley & Sons, Houghton ...
(Date:11/21/2014)... November 20, 2014 The November 2014 ... as an open access journal featuring the following articles:, ... proteins to preserve photoresponsiveness in the retina , ... in situ hybridization using chromogenic substrates in zebrafish , ... RNA, and protein electrophoresis , Nuclear LC3-positive ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
Breaking Biology Technology:Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... (NTI (R)) (Nasdaq: NTII ) today announced the ... 31, 2007., Paul Freiman, president and chief executive ... occasion of his 75th birthday. Dr.,Cape is a legend ... board,has been outstanding. Prior to joining the board, Dr. ...
... FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire-,FirstCall/ ... and GBP IP, LLC, an,affiliate of GBP Capital, ... announced that the two companies have entered,into an ... gene,delivery technology, commonly referred to as lentiviral vectors. ...
... 20 Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) ... randomized, double-blind, placebo-controlled Phase 2a clinical,trial of MEM ... in cognitive impairment associated with schizophrenia (CIAS). The,trial ... cognitive effects,of three doses of MEM 3454 in ...
Cached Biology Technology:Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 2Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 3Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 4Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 5Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
Biology Products: